Knutzen Robert, Ezzat Shereen
Pituitary Network Association, Thousand Oaks, Calif. 91358, USA.
Neuroendocrinology. 2006;83(3-4):139-44. doi: 10.1159/000095521. Epub 2006 Oct 13.
Despite ample proof to the contrary, the overwhelming number of health care practitioners still believe that acromegaly is a disease that they will rarely encounter, let alone have to treat. However, the reality is quite a bit different for both doctors and patients. Many of the obvious symptoms and signs of this disease manifest slowly and insidiously. As such, the majority of patients are often treated for seemingly unrelated conditions for years before the actual diagnosis of acromegaly is established. Thus, the overall cost of medical care for the acromegalic patient is considerably higher than appreciated at first glance. The financial cost of managing this disease must include the cost of care of comorbid conditions before and following the diagnosis of acromegaly. It is only through a higher degree of awareness that this disease will be identified earlier in its course and the true number of acromegalic patients is realized. We anticipate that such measures will serve to limit the psychological, emotional and economic burden of this potentially debilitating disease.
尽管有大量相反的证据,但绝大多数医疗从业者仍然认为肢端肥大症是一种他们很少会遇到的疾病,更不用说需要治疗了。然而,对于医生和患者来说,现实却大不相同。这种疾病的许多明显症状和体征表现缓慢且隐匿。因此,大多数患者在肢端肥大症实际确诊之前,往往会因看似无关的病症接受多年治疗。因此,肢端肥大症患者的总体医疗费用比乍一看要高得多。管理这种疾病的财务成本必须包括在肢端肥大症诊断前后治疗合并症的费用。只有通过更高程度的认识,这种疾病才能在病程中更早地被识别出来,并且才能了解肢端肥大症患者的真实数量。我们预计,这些措施将有助于减轻这种潜在致残性疾病带来的心理、情感和经济负担。